The BEAR III Trial for Bridge-Enhanced ACL (Anterior Cruciate Ligament) Restoration
Public ClinicalTrials.gov record NCT03348995. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective Cohort Clinical Trial Evaluating Age as a Risk Factor for Poor Outcomes of Bridge-Enhanced ACL Restoration (BEAR)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Bridge-Enhanced ACL Restoration (BEAR) is a new procedure being developed to treat patients with ACL injuries. In the BEAR procedure, an implant is placed between the torn ends of the ACL and the patient's own blood is added to the implant to stimulate ligament healing. We propose the current study to determine if older patients do better than younger patients (or vice versa) with this procedure. This is a cohort study designed to determine if age is a risk factor for a worse outcome after a bridge-enhanced ACL repair (BEAR) as defined by an 11.5 point difference on the IKDC Subjective or Objective Knee Evaluation score at two years after surgery. Additional objectives are to determine the effect of age on safety outcomes including infection, graft rejection, and need for further surgical procedures.
Study identification
- NCT ID
- NCT03348995
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 250 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 12 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 16, 2018
- Primary completion
- Feb 27, 2026
- Completion
- Apr 16, 2034
- Last update posted
- Jun 8, 2026
2018 – 2034
United States locations
- U.S. sites
- 11
- U.S. states
- 11
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Scripps Health | San Diego | California | 92121 | — |
| Florida Orthopedic Institute | Tampa | Florida | 33637 | — |
| Emory University School Of Medicine | Atlanta | Georgia | 30329 | — |
| Ochsner Sports Medicine Institute | New Orleans | Louisiana | 70121 | — |
| MedStar Health Surgery Center of Timonium | Lutherville | Maryland | 21093 | — |
| Boston Children's Hospital | Boston | Massachusetts | 02115 | — |
| Virtua Health | Marlton | New Jersey | 08053 | — |
| Cynthia Chrostek | Providence | Rhode Island | 02903 | — |
| Orthopedic Institute of Sioux Falls | Sioux Falls | South Dakota | 57105 | — |
| UT Southwestern | Dallas | Texas | 75390 | — |
| Inova Sports Medicine | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03348995, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03348995 live on ClinicalTrials.gov.